COUR NanoParticle technology halts Type 1 diabetes progression

COUR Pharmaceuticals has published details of a study with the Miller Lab at Northwestern University, in which treatment with the COUR NanoParticle Platform (CNP) prevented beta cell destruction in the pancreas, stopping the progression of Type 1 diabetes in non-obese diabetics (NOD).

COUR’s immune-modifying nanoparticles are designed to reprogram the immune system in treating autoimmune disorders. The CNPs’ mechanism of action is induction of regulatory T cells which inhibit the infiltration of inflammatory autoreactive T cells into the pancreas, where they would otherwise destroy insulin producing beta cells.

The findings provide proof of principle for a potential paradigm shift in the treatment of Type 1 diabetes to move patients away from life-long patient-driven management by halting the progression of disease and delaying the need for insulin.

“This is the first time a therapy has held normal glycemic levels in the NOD model, one of the most challenging models for Type 1 diabetes and autoimmunity,” said Stephen Miller, professor of microbiology-immunology. “The results of this preclinical study are very exciting and the team at COUR are passionate to bring the COUR NanoParticle Platform encapsulating human disease relevant antigens (CNP-103) into the clinic to provide a potential life changing therapy.”

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags